V
Vincent Cottin
Researcher at Claude Bernard University Lyon 1
Publications - 675
Citations - 29630
Vincent Cottin is an academic researcher from Claude Bernard University Lyon 1. The author has contributed to research in topics: Idiopathic pulmonary fibrosis & Medicine. The author has an hindex of 68, co-authored 574 publications receiving 21594 citations. Previous affiliations of Vincent Cottin include University of Lyon & Institut national de la recherche agronomique.
Papers
More filters
Journal ArticleDOI
Obstructive sleep apnoea and related comorbidities in incident idiopathic pulmonary fibrosis
Thomas Gille,Morgane Didier,Marouane Boubaya,Loris Moya,Angela Sutton,Zohra Carton,Fanny Baran-Marszak,Danielle Sadoun-Danino,Dominique Israel-Biet,Vincent Cottin,Frédéric Gagnadoux,Bruno Crestani,Marie-Pia d'Ortho,Pierre-Yves Brillet,Dominique Valeyre,Hilario Nunes,Carole Planès +16 more
TL;DR: Severe sleep apnoea syndrome is associated with cardiovascular disease in incident idiopathic pulmonary fibrosis and severe OSA is strongly associated with the presence of CVD, particularly IHD.
Journal ArticleDOI
Idiopathic interstitial pneumonias with connective tissue diseases features: A review.
TL;DR: Evidence is accumulating that even limited CTD features are relevant regarding symptoms, imaging features, pathological pattern and possibly evolution to overt CTD, whereas the impact on prognosis needs confirmation.
Journal ArticleDOI
Vinblastine chemotherapy in adult patients with langerhans cell histiocytosis: a multicenter retrospective study
Abdellatif Tazi,Gwenaël Lorillon,Julien Haroche,Antoine Néel,Stéphane Dominique,Achille Aouba,Jean-David Bouaziz,Constance de Margerie-Melon,Emmanuelle Bugnet,Vincent Cottin,Thibault Comont,Christian Lavigne,Jean-Emmanuel Kahn,Jean Donadieu,Sylvie Chevret +14 more
TL;DR: Vinblastine is an effective and well-tolerated first-line treatment for adult LCH except in patients with lung involvement and impaired lung function, however, a significant portion of patients experienced LCH reactivation during long-term follow up.
Journal ArticleDOI
Pulmonary Arterial Hypertension Associated With Systemic Lupus Erythematosus: Results From the French Pulmonary Hypertension Registry
Eric Hachulla,Xavier Jaïs,Gaël Cinquetti,Pierre Clerson,Laurence Rottat,David Launay,Vincent Cottin,Gilbert Habib,Grégoire Prévot,Céline Chabanne,Elena Fois,Zahir Amoura,Luc Mouthon,Véronique Le Guern,David Montani,Gérald Simonneau,Marc Humbert,Vincent Sobanski,Olivier Sitbon,Marie-Hélène Balquet,Jean-Marc Ziza,Jean-Pierre Clauvel,Jean-Claude Brouet,Christophe Pison,Jean-François Chabot,J.-F. Velly,Pierre-Dominique Dos Santos,Jean-Claude Meurice,Anne-Laure Fauchais,Loïc Guillevin,Jacques Cadranel,Julie Traclet,Jean-François Mornex,Philippe Mabo,Alain Didier +34 more
TL;DR: Anti‐SSA/SSB antibodies may be a risk factor for PAH, and the presence of anti‐U1‐RNP antibodies appears to be a protective factor regarding survival.
Journal ArticleDOI
Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis (EGPA): a European multicenter observational study
Alessandra Bettiol,Maria Letizia Urban,Lorenzo Dagna,Vincent Cottin,Franco Franceschini,Stefano Del Giacco,Franco Schiavon,Thomas Neumann,Giuseppe Lopalco,Pavel Novikov,Chiara Baldini,Carlo Lombardi,Alvise Berti,Federico Alberici,Marco Folci,Simone Negrini,Renato Alberto Sinico,Luca Quartuccio,Claudio Lunardi,Paola Parronchi,Frank Moosig,Georgina Espígol-Frigolé,Jan Schroeder,Anna Kernder,Sara Monti,Ettore Silvagni,Claudia Crimi,Francesco Cinetto,Paolo Fraticelli,Dario Roccatello,Angelo Vacca,Aladdin J Mohammad,Aladdin J Mohammad,Bernhard Hellmich,Maxime Samson,Elena Bargagli,Jan Willem Cohen Tervaert,Jan Willem Cohen Tervaert,Camillo Ribi,Davide Fiori,Federica Bello,Filippo Fagni,Luca Moroni,Giuseppe A. Ramirez,Mouhamad Nasser,Chiara Marvisi,Paola Toniati,Davide Firinu,Roberto Padoan,Allyson Egan,Benjamin Seeliger,Florenzo Iannone,Carlo Salvarani,David Jayne,Domenico Prisco,Augusto Vaglio,Augusto Vaglio,Giacomo Emmi +57 more
TL;DR: In this paper, the effectiveness and safety of mepolizumab 100 and 300mg/4 weeks in a large European EGPA cohort were evaluated in a randomized controlled MIRRA trial.